University Rouen Hospital
Rouen, 76031, France
NCT Number: NCT06955572
The hypothesis of METARICH Study is that it is possible to draw up a profile of the faecal microbiota, which could contribute in the future to the characterisation of certain chronic pathologies. The pathologies chosen for the study were selected because they are associated in the literature with changes in the faecal microbiota.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Rouen, 76031, France
All the study data will be collected from the patients' clinical records and from the questionnaires set up (patient inclusion questionnaire and information questionnaire).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
List of patient inclusion criteria:
Male or female patient consulting the Rouen University Hospital for one of the 4 pathologies below:
List of inclusion criteria for the control group:
Exclusion criteria
List of patient non-inclusion criteria :
List of non-inclusion criteria for the control group:
Analysis of the lower fecal gene count (fGC) compared with the control group
Analysis of the lower fecal gene count (fGC) compared with the control group
Analysis of the lower fecal gene count (fGC) compared with the control group
Analysis of the lower fecal gene count (fGC) compared with the control group
Determination of the number of bacterial faecal genes (fGC, fecal Gene Count) inferior reference
Time frame: At enrollment visit, Month 2
Measuring the gene richness of faecal microbiota in Patients with colorectal cancer arm
Time frame: At enrollment visit, Month 2
Measuring the gene richness of faecal microbiota in Patients with obesity arm
Time frame: At enrollment visit, Month 2
Measuring the gene richness of faecal microbiota in Patients with Parkinson's disease arm
Time frame: At enrollment visit, Month 2
Measuring the gene richness of faecal microbiota in Patients with non-alcoholic steatohepatitis arm
Time frame: At enrollment visit, Month 2
Measuring the gene richness of faecal microbiota in Healthy volunteers arm
Time frame: At enrollment visit, Month 2
Gene counting from metagenomic sequencing in Patients with colorectal cancer arm
Time frame: At enrollment visit, Month 2
Gene counting from metagenomic sequencing in Patients with obesity arm
Time frame: At enrollment visit, Month 2
Gene counting from metagenomic sequencing in Patients with Parkinson's disease arm
Time frame: At enrollment visit, Month 2
Gene counting from metagenomic sequencing in Patients with non-alcoholic steatohepatitis arm
Time frame: At enrollment visit, Month 2
Gene counting from metagenomic sequencing in Healthy volunteers arm
Time frame: At enrollment visit, Month 2
Creation of a metagenomic data library referencing the data collected
Time frame: At enrollment visit, Month 2
Identify a gene count threshold that discriminates against the degree of severity of the disease (colorectal cancer)
Time frame: At enrollment visit, Month 2
Identify a gene count threshold that discriminates against the degree of severity of the disease (obesity)
Time frame: At enrollment visit, Month 2
Identify a gene count threshold that discriminates against the degree of severity of the disease (Parkinson)
Time frame: At enrollment visit, Month 2
Identify a gene count threshold that discriminates against the degree of severity of the disease (non-alcoholic steatohepatitis)
University Hospital, Rouen
Other
Descriptive Study of the Gene Count in Faecal Microbiota During the Course of Various Pathologies and Correlation With the Clinical Phenotype
Acronym: METARICH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715058
Microbiota, Vaginal Microbiome
Madrid, Spain
View Trial DetailsNCT04538482
Cancer, Microbiota
Tampa, Florida, United States
View Trial DetailsNCT07527286
Bloating, Butyrate
Canfield, Ohio, United States
View Trial DetailsNCT07496502
Bacterial Infections, Bacterial Infections and Mycoses
Mexico City, Mexico
View Trial Details